Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Grants Approval for Hydromorphone Hydrochloride ANDA076444

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:31:01 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Barr's Hydromorphone Hydrochloride ANDA076444 is significant as it strengthens Barr's competitive position in the opioid market. This development necessitates a strategic assessment of market dynamics and pricing strategies within the pain management segment. Regulatory context from FDA (FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies in the opioid segment. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 7 regulatory and 0 competitive items passed relevance filtering for Barr.

Competitive Pressure

The most relevant competitive pressure comes from This approval may enhance Barr's position in the opioid market, potentially impacting competitors in pain management therapies..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (barr); Regulatory pathway relevance (nda). This approval indicates compliance with FDA standards, which may influence future submissions and approvals in the opioid category.

Key Risks

Elevated medium regulatory exposure for Barr could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Barr, impacting revenue streams and competitive positioning against other pain management therapies.
Portfolio teams should assess the implications of this approval on market share and pricing strategies in the opioid segment.

What Would Change This Assessment

This becomes more urgent if Monitor market entry strategies and sales performance of Hydromorphone Hydrochloride post-approval.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (barr); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hydromorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hydromorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hydromorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hydromorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hydromorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (barr); Regulatory pathway relevance (nda)
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Development of Pain Control Options Menu for IUD Insertion
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Clinical Practice of Hydromorphone in Multimodal Analgesia for Enhanced Recovery After Surgery (ERAS) in Knee Arthroplasty
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Barriers to satisfactory primary care contacts for Swedish cancer survivors: a cross-sectional survey.
PubMedmedium relevance
Entity match (barr)
FDA document
View source
Management of uterine fibroids: opinions on interventions and the future of services in the United Kingdom-a pilot survey.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Barr
Hydromorphone Hydrochloride
pain management therapies

Commercial impact

medium

The approval could lead to increased market share for Barr, impacting revenue streams and competitive positioning against other pain management therapies.

Regulatory impact

medium

This approval indicates compliance with FDA standards, which may influence future submissions and approvals in the opioid category.

What to watch

Monitor market entry strategies and sales performance of Hydromorphone Hydrochloride post-approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.